Loading stock data…
$2.67-0.17 (-5.99%)
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Anixa Biosciences, Inc. in the Healthcare sector is trading at $2.67 with a market capitalization of $103M. Wall Street consensus targets $9.75 (4 analysts), implying a +265.2% move over the next 12 months. The stock is currently near its 52-week low of $2.32, remaining 10.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.74M↓ | -$2.65M↑ | -$2.72M↑ | -$2.88M↓ | -$2.44M |
| Net Income | -$2.61M↓ | -$2.52M↑ | -$2.56M↑ | -$2.69M↓ | -$2.26M |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T ce...